4,809
Views
18
CrossRef citations to date
0
Altmetric
Clinical Research

The safety of high-dose insulin euglycaemia therapy in toxin-induced cardiac toxicity

ORCID Icon, ORCID Icon & ORCID Icon
Pages 389-396 | Received 26 Jun 2017, Accepted 09 Oct 2017, Published online: 26 Oct 2017
 

Abstract

Context: High-dose insulin euglycaemia (HIE) is recommended in the management of toxin-induced cardiac toxicity, with increasing insulin doses now being used. We aimed to investigate the safety of HIE in toxin-induced cardiac toxicity.

Methods: This was a retrospective review of cases from two clinical toxicology units. Demographics, toxin(s) ingested, clinical effects, investigations (serum glucose, electrolytes), treatments (insulin, glucose, electrolyte replacement), length of stay (LOS) and outcomes were extracted from the patients’ medical records. Associations between insulin and glucose/electrolyte homeostasis were explored by comparing insulin administration and glucose or electrolyte concentrations and replacement.

Results: There were 22 patients (12 females), median age 57 years (15–88 years) treated with HIE. There were 12 beta-blocker, six calcium channel blocker and three combined beta-blocker and calcium channel blocker ingestions. A total of 19 patients had a systolic blood pressure <80mmHg and 18 patients required inotropes in addition to HIE. There were three deaths. Despite glucose and electrolyte replacement, 16 patients (73%) developed hypoglycaemia (Reference range [RR] < 3.5 mmol/L or <63 mg/dl). In 7 patients, hypoglycaemia was mild (2.5–3.4 mmol/L or 45–62 mg/dl) and in nine was severe (<2.5 mmol/L or <45 mg/dl). There were no neurological effects from hypoglycaemia. A total of 18 patients (82%) developed hypokalaemia (<3.5 mEq/L). In 16 patients, this was mild (2.5–3.4 mEq/L). There were no cardiac arrhythmias associated with this hypokalaemia.

There was no apparent association between insulin dosing and severity of hypoglycaemia or hypokalaemia, or in glucose or potassium replacement. Median insulin loading dose was 80U (range 50–125 U) and the median maximum insulin infusion rate was 150 U/h (range 38–1500 U/h). Median glucose infusions rates were 37.5g/h (range 4–75g/h). There was no apparent association between insulin and glucose administration. Glucose was administered for a median of 18h after ceasing insulin. The duration of glucose administration after ceasing insulin increased with the rate and total insulin administered during HIE.

Discussion: Despite the benefits of HIE in toxin-induced cardiac toxicity, it caused significant disruption to glucose and electrolyte homeostasis, although there were no apparent complications from this. There was no association by comparing the amount of insulin administered on adverse effects or glucose administered, suggesting higher doses of insulin are associated with no more adverse effects.

Acknowledgements

We acknowledge the assistance of the medical and nursing staff both at the Calvary Mater Newcastle and Princess Alexandra Hospital’s Emergency Departments and Intensive Care Units.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

Colin B. Page is funded by an Emergency Medicine Foundation research fellowship. Nicole M. Ryan is funded by an NHMRC Early Career Fellowship Award ID 1072056. Geoffrey K. Isbister is funded by an NHMRC Senior Research Fellowship ID 1061041.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.